Biotech Tracker
MilestoneH2 2026a window, not a day

FDA engagement on votoplam PIVOT-HD 24-month results in Huntington's disease

FDA engagement on votoplam PIVOT-HD 24-month results in Huntington's disease, expected in the second half of 2026 (no exact date yet). A company milestone for PTC (votoplam (PTC518) for Huntington's disease): a step in the program rather than a decision or a data readout.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsCompany milestone
Company
PTC Therapeutics, Inc. PTCT
Drug
votoplam (PTC518)
For
Huntington's disease
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day; the calendar never invents one
Source note
Company plans to engage with FDA in 2H 2026 to discuss PIVOT-HD 24-month results; outcome frames a potential accelerated path for the Novartis-partnered program.
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
PTC Therapeutics, Inc.
2 upcoming · 4 past catalysts
More from PTCT
MilestonePTCTPTC2027

PTC303 (MSH3 splicing) clinical entry, expected during 2027 (no exact date yet). A company milestone for PTC (PTC303 for somatic expansion disorders (Huntington's disease, myotonic dystrophy)): a step in the program rather than a decision or a data readout.

More details
Entry
PTC303 (MSH3 splicing) clinical entry · Company milestone
Drug
PTC303
For
somatic expansion disorders (Huntington's disease, myotonic dystrophy)
Stage
Phase 1 · an early safety study in a small group of people
When
2027 · the company gave a window, not a day
Source note
Company plans to enter the clinic in 2027 (year-level guidance only).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page